If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Five batches across four programs of Biocon Academy participated in the graduation ceremony
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
New facility is part of Aptar Pharma’s global expansion program
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated
